Titan Pharmaceuticals Schedules Conference Call to Review First Quarter 2013 Financial Results May 9, 2013
Titan Pharmaceuticals Receives Complete Response Letter From the FDA for Probuphine New Drug Application May 1, 2013
Titan Pharmaceuticals' Probuphine Program to Be Presented at ASAM Medical-Scientific Conference and APA Annual Meeting April 22, 2013
Titan Pharmaceuticals Announces FDA Advisory Committee Recommends Approval of Probuphine for the Treatment of Adult Patients With Opioid Dependence March 21, 2013
Titan Pharmaceuticals Schedules Conference Call to Review Fourth Quarter and Full Year 2012 Financial Results March 11, 2013
Titan Pharmaceuticals Announces Date of FDA Advisory Committee Review of Probuphine(R) for the Treatment of Opioid Dependence February 27, 2013
Probuphine(R) Receives FDA Priority Review Designation for Adult Patients With Opioid Dependence January 2, 2013
Titan Pharmaceuticals Licenses Exclusive Probuphine(R) Commercialization Rights in U.S. and Canada to Braeburn Pharmaceuticals December 17, 2012
